SCHEMBL6028868

SCHEMBL6028868

CCOC(C(=O)O)n1cccc(Nc2cccc(OC)c2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MTNR1B P49286 5/20 0.49
AKR1C3 P42330 3/20 0.46
AKR1C2 P52895 3/20 0.46
PTGER3 P43115 9/20 0.46
KDM4E B2RXH2 4/20 0.46
MEN1 O00255 2/20 0.46
ALDH1A1 P00352 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 1/20 0.46
GAA P10253 1/20 0.46
GFER P55789 1/20 0.46
MTNR1A P48039 3/20 0.46
MAPT P10636 3/20 0.45
RAB9A P51151 2/20 0.45
MAPK1 P28482 1/20 0.44
RECQL P46063 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6027954 0.92 MTNR1B (0.49) MTNR1BAKR1C3AKR1C2PTGER3KDM4E
Acetic Acid SCHEMBL6028849 0.80 F2 (0.48) PTGER3KDM4EMEN1ALDH1A1KMT2A
SCHEMBL6028255 0.79 OPRK1 (0.45) KDM4ENPC1GAAMAPTRAB9A
SCHEMBL6079412 0.76 PTGER3 (0.39) PTGER3KDM4EMEN1ALDH1A1KMT2A
SCHEMBL6028718 0.76 PTGER3 (0.39) PTGER3KDM4EMEN1ALDH1A1KMT2A
SCHEMBL6028532 0.70 F2 (0.47)
SCHEMBL1961347 0.68 AKR1C3 (0.57) MTNR1BAKR1C3AKR1C2MEN1KMT2A
SCHEMBL11540106 0.67 AKR1C3 (0.79) AKR1C3AKR1C2MEN1KMT2ANPC1
SCHEMBL7161900 0.66 AKR1C3 (0.58) MTNR1BAKR1C3AKR1C2MEN1KMT2A
SCHEMBL1921497 0.66 MEN1 (0.62) MTNR1BAKR1C3AKR1C2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1706396-A1 N-(4-CARBAMIMIDOYL-BENZYL)-2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA F.HOFFMANN-LA ROCHE AG (CH) 2006-10-04 EP disclosed
US-7056932-B2 Heterocyclyl substituted 1-alkoxy acetic acid amides HOFFMAN-LA ROCHE INC. (US) 2006-06-06 US disclosed
WO-2005058868-A1 N-(4-CARBAMIMIDOYL-BENZYL) -2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137168-A1 Heterocyclyl substituted 1-alkoxy acetic acid amides HOFFMANN-LA ROCHE INC. 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137168-A1 Heterocyclyl substituted 1-alkoxy acetic acid amides F12, TFPI, F11 MTNR1B 1992/4885AKR1C3 94/4885AKR1C2 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.